Linagliptina/Metformina Stada

Linagliptin/Metformin, the active ingredients in Linagliptina/Metformina Stada, are a combination of a DPP‑4 inhibitor and a biguanide presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adult patients who need additional glycaemic control beyond diet and exercise.

GNH USA supplies Linagliptina/Metformina Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptina/Metformina is indicated for the management of type 2 diabetes mellitus, acting on glucose metabolism pathways.

- Type 2 diabetes mellitus: improves overall glycaemic control when used with diet and exercise. - Inadequate control on metformin alone: provides additional glucose‑lowering effect as part of combination therapy. - Metformin intolerance: offers an alternative DPP‑4 inhibitor component for patients who cannot tolerate high‑dose metformin.

The following adverse reactions have been reported with the combination of linagliptin and metformin.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhoea: loose stools, often transient. - Headache: mild tension‑type headaches. - Dizziness: occasional light‑headedness. - Hypoglycaemia (when combined with sulfonylureas or insulin): low blood sugar episodes. - Abdominal discomfort: bloating or cramping.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Hepatic failure: signs of liver dysfunction. - Acute kidney injury: reduced renal function. - Severe hypoglycaemia: especially in patients with renal impairment.

Before initiating therapy, clinicians should consider several safety aspects.

- Renal function monitoring: assess eGFR and adjust dose if needed. - Hepatic function monitoring: evaluate liver enzymes periodically. - Contraindicated in severe renal impairment: avoid use when eGFR <30 mL/min/1.73 m². - Use with caution in heart failure: monitor for fluid overload. - Pregnancy and breastfeeding: only if benefits outweigh potential risks. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Linagliptina/Metformina may interact with other medicines; interactions are grouped by clinical relevance.

Major Interactions (Avoid): - Iodinated contrast agents: can precipitate acute renal failure with metformin. - Cimetidine: may increase metformin plasma concentrations. - Trimethoprim: can raise metformin levels and risk lactic acidosis. - Strong CYP3A4 inhibitors: may affect linagliptin exposure. - Alcohol excess: enhances risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: monitor renal function and potassium. - Diuretics: may affect fluid and electrolyte balance. - NSAIDs: increase risk of renal impairment. - Beta‑blockers: may mask hypoglycaemia symptoms. - Sulfonylureas or insulin: monitor for additive hypoglycaemia.